Drugs / CART30
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02259556 | Oct 2014 → Oct 2018 overdue | Hodgkins lymphoma, non-Hodgkin lymphoma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02259556 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor-modified T cells (CART) holds great promise for treatment of tumors.” NCT02259556 ↗ |
| Route | Intravenous | “infusions of CART30 cells into the vein” NCT02259556 ↗ |